Clinical efficacy of sitaliptin with metmorphine in patients with type 2 diabetes mellitus and coronary heart disease on the background of statins

Abstract

Type 2 diabetes mellitus (DM2) is a chronic progressive disease. Experts from the World Diabetes Association predict an increase in the number of patients with diabetes by 2030 by 1.5 times and will reach 552 million people i.e. every 10th inhabitant of the planet will get sick[1]. Half of patients with type 2 diabetes already have complications, including from the cardiovascular system, by the time the disease manifests itself. By the age of 50, almost 50% of diabetic patients have at least one of them unstable angina, myocardial infarction, lifethreatening cardiac arrhythmias, and chronic heart failure rapidly develops. In this regard, the main strategy for the treatment of patients with diabetes is to prevent the development of cardiovascular complications, which includes strict control of glycemia, blood pressure, as well as antiplatelet and lipid-lowering therapy. Despite the fact that strict glycemic control alone does not reduce the risk of myocardial infarction and mortality from it, most epidemiological and pathophysiological studies indicate a worse prognosis and a higher incidence of cardiovascular complications in chronic hyperglycemia. The use of a fixed combination of sitagliptin/metformin plus statins in our study is one of the preferred options for the treatment of type 2 diabetes in patients with a high risk of cardiovascular disease, since type 4 dipeptidyl peptidase inhibitors have a cardioprotective effect